A detailed history of Rbf Capital, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Rbf Capital, LLC holds 350,000 shares of ALLK stock, worth $224,000. This represents 0.02% of its overall portfolio holdings.

Number of Shares
350,000
Holding current value
$224,000
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.0 - $1.45 $350,000 - $507,500
350,000 New
350,000 $350,000
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $563,453 - $1.14 Million
-186,574 Reduced 65.13%
99,900 $611,000
Q2 2022

Aug 15, 2022

SELL
$2.6 - $6.14 $183,835 - $434,134
-70,706 Reduced 19.8%
286,474 $897,000
Q1 2022

May 16, 2022

SELL
$5.08 - $9.81 $176,230 - $340,318
-34,691 Reduced 8.85%
357,180 $2.03 Million
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $3.35 Million - $43.8 Million
391,871 New
391,871 $3.84 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $54.2M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Rbf Capital, LLC Portfolio

Follow Rbf Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.